Rare drug royalties, life sciences backed deals hit ABS primary
A pair of pharmaceutical and healthcare ABS offerings tested investors’ appetites for a range of esoteric ABS assets following the US Memorial Day weekend.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast